Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Xenomics has granted Warnex Medical Laboratories, a division of Warnex, nonexclusive rights in Canada to offer NPM1 testing as a laboratory service for the diagnosis, stratification and monitoring of patients with Acute Myeloid Leukemia or AML.
Subscribe to our email newsletter
The NPM1 mutation may also be used to monitor AML patients for residual disease during chemotherapy. Stratification of AML patients is also necessary for anti-AML drug clinical trials.
Xenomics has nonexclusively sublicensed its diagnostic applications to Warnex to offer clinical testing. The diagnostic test will help physicians select patients with a good prognosis of benefiting from intensive chemotherapy, while sparing others with a low probability of benefit from the toxic treatment.